New anticancer therapeutics require extensive characterization to identify endogenous and exogenous factors affecting efficacy, to measure toxicity and mutagenicity, and to determine genotypes that result in therapeutic sensitivity or resistance. We used as a platform with which to characterize properties of the anticancer therapeutic CX-5461. To understand the processes that respond to CX-5461-induced damage, we generated pharmacogenetic profiles for a panel of DNA replication and repair mutants with common DNA-damaging agents for comparison with the profile of CX-5461. We found that multiple repair pathways, including homology-directed repair, microhomology-mediated end joining, nucleotide excision repair, and translesion synthesis, were needed for CX-5461 tolerance. To determine the frequency and spectrum of CX-5461-induced mutations, we used a genetic balancer to capture CX-5461-induced mutations. We found that CX-5461 is mutagenic, resulting in both large copy number variations and a high frequency of single-nucleotide variations (SNVs), which are consistent with the pharmacogenetic profile for CX-5461. Whole-genome sequencing of CX-5461-exposed animals found that CX-5461-induced SNVs exhibited a distinct mutational signature. We also phenocopied the CX-5461 photoreactivity observed in clinical trials and demonstrated that CX-5461 generates reactive oxygen species when exposed to UVA radiation. Together, the data from demonstrate that CX-5461 is a multimodal DNA-damaging anticancer agent.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7337070 | PMC |
| http://dx.doi.org/10.1534/genetics.120.303169 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
RBIS regulates ribosome biogenesis to affect progression in lung adenocarcinoma.
J Transl Med
December 2024
Cancer Institute, Fudan University Shanghai Cancer Center, Shanghai, 200032, China.
Background: Increased ribosome biogenesis is required for tumor growth. In this study, we investigated the function and underlying molecular mechanism of ribosome biogenesis factor (RBIS) in the progression of non-small cell lung cancer (NSCLC).
Methods: In our study, we conducted a comprehensive analysis to identify key genes implicated in ribosome biogenesis by leveraging a Gene Set Enrichment Analysis (GSEA) dataset.
G-quadruplex stabilizer CX-5461 effectively combines with radiotherapy to target ATRX-deficient malignant glioma.
Neuro Oncol
November 2024
Department of Translational Molecular Pathology, The University of Texas MD Anderson Cancer Center, Houston, TX, 77030, USA.
Article Synopsis
- Inactivation of the ATRX gene is a key feature of malignant gliomas, leading to G-quadruplex (G4) DNA structures that cause replication stress and genomic instability.
- The study tested a drug, CX-5461, on glioma stem cells and mouse models, both alone and with radiation, showing it was particularly effective against ATRX-deficient tumors.
- The results revealed that CX-5461 increased DNA damage and cell death specifically in ATRX-deficient models, reduced tumor growth, and improved survival in mice, highlighting its potential as a new treatment approach for this type of cancer.
The unique Pt(II)-induced nucleolar stress response and its deviation from DNA damage response pathways.
J Biol Chem
November 2024
Department of Chemistry and Biochemistry, University of Oregon, Eugene, Oregon, USA. Electronic address:
The mechanisms of action for the platinum compounds cisplatin and oxaliplatin have yet to be fully elucidated, despite the worldwide use of these drugs. Recent studies suggest that the two compounds may be working through different mechanisms, with cisplatin inducing cell death via the DNA damage response (DDR) and oxaliplatin utilizing a nucleolar stress-based cell death pathway. While cisplatin-induced DDR has been subject to much research, the mechanisms for oxaliplatin's influence on the nucleolus are not well understood.
View Article and Find Full Text PDFMolecular basis of CX-5461-induced DNA damage response in primary vascular smooth muscle cells.
Heliyon
September 2024
Gerontology and Anti-Aging Research Laboratory, Department of Geriatric Medicine, Qilu Hospital of Shandong University, Jinan, Shandong Province, China.
Article Synopsis
- CX-5461 is a selective RNA polymerase I inhibitor that suppresses the growth of vascular smooth muscle cells by triggering a DNA damage response (DDR) involving ATM/ATR and p53 activation.
- The study focused on primary aortic smooth muscle cells to investigate the mechanisms of CX-5461-induced DDR, finding that it activates homologous recombination but does not cause significant DNA double strand breaks.
- The primary cause of the DDR in these cells appears to be DNA replication stress, which may be linked to increased conflict between DNA replication and transcription rather than specific DNA structures.
Fibroblast growth receptor 1 is regulated by G-quadruplex in metastatic breast cancer.
Commun Biol
August 2024
Borch Department of Medicinal Chemistry and Molecular Pharmacology, Purdue University, West Lafayette, IN, USA.
Limiting cellular plasticity is of key importance for the therapeutic targeting of metastatic breast cancer (MBC). Fibroblast growth receptor (FGFR) is a critical molecule in cellular plasticity and potent inhibitors of FGFR enzymatic activity have been developed, but kinase independent functions for this receptor also contribute to MBC progression. Herein, we evaluated several FGFR inhibitors and find that while FGFR-targeted kinase inhibitors are effective at blocking ligand-induced cell growth, dormant cells persist eventually giving rise to MBC progression.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!